Eli Lilly, Merck, and Novo Nordisk are competing in the GLP-1 economics market, with Novo Nordisk referencing a SUSE cardiovascular trial.

The entities involved

• Eli Lilly and Company →

  American pharmaceutical company

  • Houthis actions and Iran's geopolitical moves are elevating gas prices, prompting investors to rotate into safer, low-growth sectors.Mon 15:45
  • Orna Therapeutics was acquired by Eli Lilly and Company, a development within the RNA therapeutics sector.Mon 15:43
• Merck →

  public company in Indonesia

  • Merck forged a strategic alliance with R-Pharm on November 1, 2026.Mon 06:38
  • AstraZeneca formed a partnership with Daiichi Sankyo regarding Enhertu, and also established a profit-sharing deal with Merck for Lynparza.Sun 14:45
• Novo Nordisk →

  Danish pharmaceutical company

  • Major pharmaceutical companies, including Viking Therapeutics, Eli Lilly, and Novo Nordisk, are advancing their weight loss drug pipelines.Mon 13:49
  • Eli Lilly and Company received full FDA approval, expanded a safety study into India, and broke ground on a new facility in Houston while competing in the GLP-1 market.Fri 19:45

Related events

• Major pharmaceutical companies, including Pfizer, Amgen, Eli Lilly, and Novo Nordisk, are leading the market in next-generation GLP-1 drugs for weight loss and diabetes.Jun 10
• BMS, Eli Lilly, and Novo Nordisk are advancing GLP-1 portfolios, investing in manufacturing, and navigating regulatory approvals.Oct 22
• Eli Lilly and Novo Nordisk are competing for market share in the weight loss drug sector.Jun 18
• Novo Nordisk and Astellas Pharma are noted as large-cap healthcare companies, with Novo Nordisk reporting higher revenue and earnings.Oct 23
• Eli Lilly's tirzepatide proved more effective than Novo Nordisk's semaglutide in the obesity drug market.Jun 8